Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?

Frontiers in Oncology

Bin Fan¹  Zhikun Lin²  Lili Yang²  Jian Du²  Feiliyan Maimaiti²  Jiangning Gu²  Xiang Chen²  Yunlong Chen²  Chenqi Wang²  Haifeng Luo²  Qingzhu Duan²  Guang Tan²  Jie Zhang³  Dan Chen⁴ 

[1] Department of General Surgery, The First Hospital of Northwest University (Xi’an No. 1 Hospital), Xi’an, China;Department of Hepatobiliary Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, China;Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China;Department of Pathology, The First Affiliated Hospital of Dalian Medical University, Dalian, China;

关键词: neoadjuvant chemotherapy;    neoadjuvant chemoradiotherapy;    borderline resectable;    locally advanced;    FOLFIRINOX;    gemcitabin;   

DOI  :  10.3389/fonc.2022.828223

来源: DOAJ

【 摘 要 】

The incidence of pancreatic ductal adenocarcinoma (PDAC) has been on the rise in recent years; however, its clinical diagnosis and treatment remain challenging. Although surgical resection remains the only chance for long-term patient survival, the likelihood of initial resectability is no higher than 20%. Neoadjuvant therapy (NAT) in PDAC aims to transform the proportion of inoperable PDACs into operable cases and reduce the likelihood of recurrence to improve overall survival. Ongoing phase 3 clinical trial aims to validate the role of NAT in PDAC therapy, including prolongation of survival, increased R0 resection, and a higher proportion of negative lymph nodes. Controversies surrounding the role of NAT in PDAC treatment include applicability to different stages of PDAC, chemotherapy regimens, radiation, duration of treatment, and assessment of effect. This review aims to summarize the current progress and controversies of NAT in PDAC.

【 授权许可】

Unknown